Pneumococcal vaccine study for adults aged 18 to 49
Treatments studied
Part of Infections clinical trials.
This study tests a new pneumococcal vaccine to see if it is safe and triggers a good immune response. It may help protect you from infections like pneumonia, but you must not have had any pneumococcal vaccine since age 5.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 49 years old.
- You have not received any pneumococcal vaccine (like Pneumovax or Prevnar) after age 5.
- You do not have serious chronic medical conditions (like heart, lung, or kidney disease).
- You have no history of severe allergic reactions to vaccines or their ingredients.
- You are not pregnant or breastfeeding, and agree to use contraception if applicable.
- You have no immune system problems or conditions like sickle cell disease (asplenia) or bleeding disorders.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new vaccine to protect infants from pneumococcal disease (a serious bacterial infection). Researchers want to see how well the vaccine works and how safe it is in healthy babies aged 2–6 months.
This trial tests a catch-up pneumococcal vaccine for children and adolescents who may have missed some doses. It aims to see how safe and effective the vaccine is in healthy kids aged 15 months to 17 years.
This trial tests whether a pneumococcal vaccine can help protect against a specific type of pneumonia bacteria. Researchers want to see if the vaccine can create antibodies that work against multiple strains.
This study tests a new pneumococcal vaccine (PCV15) to see how well it protects against carrying the bacteria that can cause pneumonia. Healthy adults aged 18–50 who have not had a pneumococcal vaccine in the last 5 years may join.
This study tests whether a new pneumococcal vaccine (which protects against a serious bacterial infection) is safe in healthy 2-month-old infants. Researchers will watch for side effects and help protect future babies from pneumococcal disease.
This trial tests a new 23-valent pneumococcal vaccine to see if it safely protects healthy people against pneumonia and other infections caused by pneumococcal bacteria.
Hear when a new Pneumococcal Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.